Literature DB >> 18753121

AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.

Marlene Smurzynski1, Ann C Collier, Susan L Koletar, Ronald J Bosch, Kunling Wu, Barbara Bastow, Constance A Benson.   

Abstract

PURPOSE: ALLRT is a longitudinal cohort study of HIV-infected subjects prospectively randomized into selected clinical trials for antiretroviral (ARV) treatment-naïve and ARV treatment-experienced individuals conducted by the AIDS Clinical Trials Group (ACTG). We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy.
METHOD: Standardized visits occur every 16 weeks to evaluate long-term clinical, virologic, and immunologic outcomes associated with ARV treatment.
RESULTS: A total of 4,371 subjects enrolled in ALLRT from January 2000 through June 2007. Of these, 3,146 (72%) were ARV naïve at parent study entry (18% female, 44% white, 32% black, 21% Hispanic; median age 37 years, CD4 count 218 cells/microL, follow-up 3.6 years; 343 [11%] followed > or = 8 years) and 1,225 (28%) were treatment experienced (13% female, 59% white, 20% black, 17% Hispanic; median age 42 years, CD4 count 325 cells/microL, follow-up 5.7 years).
CONCLUSIONS: ALLRT provides the opportunity to understand long-term ramifications of therapeutic ARV choices and determine whether these vary by treatment regimen, timing of treatment initiation, or treatment changes over long-term follow-up. Investigations based on uniform data and specimen collection in the context of randomized ARV treatments will be critical to developing more successful long-term therapeutic strategies for HIV treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753121      PMCID: PMC2704053          DOI: 10.1310/hct0904-269

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  37 in total

1.  Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

Authors:  Alan L Landay; John Spritzler; Harold Kessler; Donna Mildvan; Minya Pu; Larry Fox; Dorothy O'Neil; Barbara Schock; Daniel Kuritzkes; Michael M Lederman
Journal:  J Infect Dis       Date:  2003-11-13       Impact factor: 5.226

2.  The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.

Authors:  D Vlahov; J C Anthony; A Munoz; J Margolick; K E Nelson; D D Celentano; L Solomon; B F Polk
Journal:  NIDA Res Monogr       Date:  1991

3.  Interval and clinical cohort studies: epidemiological issues.

Authors:  Bryan Lau; Stephen J Gange; Richard D Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2007-06       Impact factor: 2.205

4.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

5.  Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Robert W Shafer; Laura M Smeaton; Gregory K Robbins; Victor De Gruttola; Sally W Snyder; Richard T D'Aquila; Victoria A Johnson; Gene D Morse; Mostafa A Nokta; Ana I Martinez; Barbara M Gripshover; Pamposh Kaul; Richard Haubrich; Mary Swingle; S Debra McCarty; Stefano Vella; Martin S Hirsch; Thomas C Merigan
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

6.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

Authors:  R A Kaslow; D G Ostrow; R Detels; J P Phair; B F Polk; C R Rinaldo
Journal:  Am J Epidemiol       Date:  1987-08       Impact factor: 4.897

8.  The prevalence and incidence of neurocognitive impairment in the HAART era.

Authors:  Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

9.  Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.

Authors:  Robert C Kalayjian; Nora Franceschini; Samir K Gupta; Lynda A Szczech; Ezekiel Mupere; Ronald J Bosch; Marlene Smurzynski; Jeffrey M Albert
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

10.  A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.

Authors:  Sharon A Riddler; Hongyu Jiang; Allan Tenorio; Hairong Huang; Daniel R Kuritzkes; Edward P Acosta; Alan Landay; Barbara Bastow; David W Haas; Karen T Tashima; Mamta K Jain; Steven G Deeks; John A Bartlett
Journal:  Antivir Ther       Date:  2007
View more
  61 in total

1.  Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials.

Authors:  Lynn E Taylor; Marisa Holubar; Kunling Wu; Ronald J Bosch; David L Wyles; John A Davis; Kenneth H Mayer; Kenneth E Sherman; Karen T Tashima
Journal:  Clin Infect Dis       Date:  2011-01-31       Impact factor: 9.079

2.  Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.

Authors:  Konstantia Angelidou; Peter W Hunt; Alan L Landay; Cara C Wilson; Benigno Rodriguez; Steven G Deeks; Ronald J Bosch; Michael M Lederman
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

3.  Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.

Authors:  Hamza Coban; Kevin Robertson; Marlene Smurzynski; Supriya Krishnan; Kunling Wu; Ronald J Bosch; Ann C Collier; Ronald J Ellis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

4.  No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

Authors:  Heather J Ribaudo; Constance A Benson; Yu Zheng; Susan L Koletar; Ann C Collier; Judith J Lok; Marlene Smurzynski; Ronald J Bosch; Barbara Bastow; Jeffrey T Schouten
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

5.  Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu
Journal:  Oncology       Date:  2011-05-23       Impact factor: 2.935

6.  The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.

Authors:  Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

7.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

8.  Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Authors:  Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

9.  Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.

Authors:  Jordan E Lake; Kunling Wu; Sara H Bares; Paula Debroy; Catherine Godfrey; John R Koethe; Grace A McComsey; Frank J Palella; Katherine Tassiopoulos; Kristine M Erlandson
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

10.  Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Authors:  Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch
Journal:  HIV Clin Trials       Date:  2013 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.